HMD
Director Trades
| Date | Director | Value |
|---|
Company News
Market wrap: rally continues despite disappointing mining stocks
A broad-based rise in banking, healthcare and technology stocks helped to overcome disappointing share price falls by miners dragged down by lower commodity prices. By the market close on Friday the ASX 200 finished up 0.3% or 26.6 points higher at 7796 points, representing a 0.9% gain for the week after the Reserve Bank held […]
HeraMED’s digital maternity care platform HeraCARE logs record user growth
Digital maternity care specialist HeraMED (ASX: HMD) continues to attract strong support for its unique HeraCARE platform. The end-to-end digital maternity monitoring and management platform has reached a record number of accumulated users, with further strong growth forecast. According to HeraMED, the number registered on the HeraCARE platform as of 15 June 2024 reached 3,533—representing […]
HeraMED teams up with eCare21 to deliver smart solution for in-home maternity care to US patients
Maternity-focused technology start-up HeraMED (ASX: HMD) has signed an agreement with US virtual care provider eCare21 to integrate its smart pregnancy monitoring solutions into eCare21’s software-as-a-service (SaaS) platform. Under the agreement, the digital HeraCARE platform – including the clinically-validated, in-home foetal and maternal heart rate monitor HeraBEAT – will be fully integrated into eCare21’s platform […]
HeraMED in ‘advanced discussions’ for roll-out of telehealth maternity software as COVID-19 rampages
Maternity telehealth company HeraMED (ASX: HMD) revealed this morning in a conference call it was in “advanced discussions” regarding the expedited commercial roll-out of its platform across the US, UK, Australia and Israel. The company’s HeraCARE maternity telehealth platform enables health professionals to monitor pregnant women from their homes and includes the HeraBEAT foetal heart […]
HeraMED sets sights on US market after FDA approval for ultrasonic foetal heart rate monitor
Medical data and technology developer HeraMED (ASX: HMD) has been granted key regulatory approval for its foetal ultrasonic heart rate monitor in the US after undergoing a premarket review process for the past six months. The US Food and Drug Administration (FDA) granted HerdMED with 510(k) clearance for its HeraBEAT device thereby enabling direct market entry […]
HeraMED lists on the ASX following TGA approval for HeraBEAT pregnancy home-monitoring device
Med-tech company HeraMED (ASX: HMD) has successfully listed on the Australian Stock Exchange following an oversubscribed $6 million capital raising. Funds will be used to accelerate the company’s commercialisation of its HeraBEAT product in Israel, along with the UK and Germany. HeraBEAT is a smartphone-based app that enables expectant parents to hear and monitor a fetal […]